Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer's disease
Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer's disease Neuroinflammation collaboration targeting inflammasome steps-up-the-pace in race for Alzheimer's disease medicines that alleviate the burden of devastating disease Exscientia, a leading AI Drug Discovery company, has today announced its collaboration with the Alzheimer's Research UK University of Oxford Drug Discovery Institute (ARUK-ODDI) to develop medicines targeting neuroinflammation for the treatment of Alzheimer's disease (AD). AD is the most common form of dementia worldwide, wit...
Source: finanznachrichten.de